JP2004534062A5 - - Google Patents

Info

Publication number
JP2004534062A5
JP2004534062A5 JP2003503615A JP2003503615A JP2004534062A5 JP 2004534062 A5 JP2004534062 A5 JP 2004534062A5 JP 2003503615 A JP2003503615 A JP 2003503615A JP 2003503615 A JP2003503615 A JP 2003503615A JP 2004534062 A5 JP2004534062 A5 JP 2004534062A5
Authority
JP
Japan
Prior art keywords
difumarate
phenylglycinyl
indole
carbonyl
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003503615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534062A (ja
Filing date
Publication date
Priority claimed from PCT/GB2001/002553 external-priority patent/WO2001096323A1/en
Application filed filed Critical
Priority claimed from PCT/US2002/016569 external-priority patent/WO2002100847A2/en
Publication of JP2004534062A publication Critical patent/JP2004534062A/ja
Publication of JP2004534062A5 publication Critical patent/JP2004534062A5/ja
Pending legal-status Critical Current

Links

JP2003503615A 2001-06-12 2002-06-06 Ｘａ因子インヒビター Pending JP2004534062A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2001/002553 WO2001096323A1 (en) 2000-06-13 2001-06-12 Serine protease inhibitors
US33929501P 2001-12-12 2001-12-12
PCT/US2002/016569 WO2002100847A2 (en) 2001-06-12 2002-06-06 Factor xa inhibitor

Publications (2)

Publication Number Publication Date
JP2004534062A JP2004534062A (ja) 2004-11-11
JP2004534062A5 true JP2004534062A5 (enExample) 2005-12-22

Family

ID=41210812

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003503615A Pending JP2004534062A (ja) 2001-06-12 2002-06-06 Ｘａ因子インヒビター

Country Status (13)

Country Link
US (1) US20040162295A1 (enExample)
EP (1) EP1397348B1 (enExample)
JP (1) JP2004534062A (enExample)
AR (1) AR036048A1 (enExample)
AT (1) ATE305452T1 (enExample)
AU (1) AU2002348501A1 (enExample)
DE (1) DE60206376T2 (enExample)
ES (1) ES2248618T3 (enExample)
MY (1) MY137876A (enExample)
PE (1) PE20030198A1 (enExample)
SV (1) SV2003001085A (enExample)
TW (1) TWI257389B (enExample)
WO (1) WO2002100847A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003010160A2 (en) * 2001-07-26 2003-02-06 Eli Lilly And Company 1-glycinyl-4 (methylpiperidin-4-yl) piperazines and -piperridines as factor xa antagonists
HRP20040900B1 (en) 2002-04-01 2006-02-28 Eli Lilly And Company Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor x<sub>a</sub>
CA2570634A1 (en) * 2004-06-30 2006-02-02 Eli Lilly And Company 1 (indole-6-carbonyl-d-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine d-tartrate
KR100849242B1 (ko) * 2004-06-30 2008-07-29 일라이 릴리 앤드 캄파니 1(인돌-6-카르보닐-ｄ-페닐글리시닐)-4-(1-메틸피페리딘-4-일) 피페라진 ｄ-타르트레이트
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2375920A1 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds

Similar Documents

Publication Publication Date Title
JP2003503454A5 (enExample)
JP2009541216A5 (enExample)
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
UA90545C2 (ru) Твердая фармацевтическая лекарственная форма для перорального введения с быстрым высвобождением ингибитора фактора ха свертывания крови
SE0102300D0 (sv) Compounds
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
MXPA06001838A (es) Sales de succinato y malonato de la trans-4- ((ir, 3s)-6 -cloro-3- fenilindan -1-il)-1, 2, 2- trimetilpiperazina y su uso como medicamento.
NO20052883L (no) Nye medikamenter for behandling av kronisk obstruktiv luftveissykdom.
UA83182C2 (en) Compounds effecting glucokinase
AR104979A2 (es) Derivados de quinazolina y formas cristalinas del mismo como inhibidores de vegfr
SE0104340D0 (sv) New compounds
ATE369353T1 (de) Medizinisch verwendbare arylethanolamin verbindungen
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
WO2006086447A3 (en) Pyridazine derivatives and their use as therapeutic agents
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
JP2008513510A5 (enExample)
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
JP2003526626A5 (enExample)
WO2007038112A3 (en) Combination of rosiglitazone and donepezil for improvement of cognitive function
JP2004534062A5 (enExample)
JP2005508963A5 (enExample)
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
SG137850A1 (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
DE50312523D1 (de) Pharmazeutische wirkstoffkombination sowie deren verwendung
JP2008513426A5 (enExample)